{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:42:21Z","timestamp":1783615341087,"version":"3.55.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.toxicon.2011.04.019","type":"journal-article","created":{"date-parts":[[2011,5,22]],"date-time":"2011-05-22T14:58:26Z","timestamp":1306076306000},"page":"1-7","source":"Crossref","is-referenced-by-count":34,"title":["Flu-like symptoms following botulinum toxin therapy"],"prefix":"10.1016","volume":"58","author":[{"given":"Jose F.","family":"Baizabal-Carvallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pappert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2011.04.019_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2133.2007.07764.x","article-title":"The Greek experience with efalizumab in psoriasis from a university dermatologic hospital","volume":"156","author":"Antoniou","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.toxicon.2011.04.019_bib2","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1016\/j.molimm.2008.06.031","article-title":"Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment","volume":"45","author":"Atassi","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.toxicon.2011.04.019_bib3","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1161\/01.STR.31.10.2402","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (dysport) with placebo in upper limb spasticity after stroke","volume":"31","author":"Bakheit","year":"2000","journal-title":"Stroke"},{"key":"10.1016\/j.toxicon.2011.04.019_bib4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1001\/jama.2010.907","article-title":"A 29-year-old woman with flu-like symptoms: review of influenza diagnosis and treatment","volume":"304","author":"Barry","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.toxicon.2011.04.019_bib5","first-page":"508","article-title":"A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow\u2019s feet: a double-blinded, placebo-controlled trial","volume":"29","author":"Baumann","year":"2003","journal-title":"Dermatol. Surg"},{"key":"10.1016\/j.toxicon.2011.04.019_bib6","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-4632.2004.02531.x","article-title":"Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis","volume":"44","author":"Baumann","year":"2005","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.toxicon.2011.04.019_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00042728-200503000-00002","article-title":"Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis","volume":"31","author":"Baumann","year":"2005","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2011.04.019_bib8","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","article-title":"A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia","volume":"64","author":"Benecke","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2011.04.019_bib9","first-page":"267","article-title":"Botulinum toxin A injection for cervical dystonia","volume":"47","author":"Bhaumik","year":"1999","journal-title":"J. Assoc. Physicians India"},{"key":"10.1016\/j.toxicon.2011.04.019_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1749-799X-4-34","article-title":"Botulinum toxin type A injections for the management of muscle tightness following total hip arthroplasty: a case series","volume":"4","author":"Bhave","year":"2009","journal-title":"J. Orthop. Surg. Res."},{"key":"10.1016\/j.toxicon.2011.04.019_bib11","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/j.1471-4159.2009.06093.x","article-title":"Cell entry strategy of clostridial neurotoxins","volume":"109","author":"Binz","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.toxicon.2011.04.019_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0093-7754(01)90232-5","article-title":"Dosing regimens and main adverse events of bisphosphonates","volume":"28","author":"Body","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.toxicon.2011.04.019_bib13","first-page":"1","article-title":"Botulinum toxin type A in the treatment of patients with cervical dystonia","volume":"3","author":"Brashear","year":"2009","journal-title":"Biologics"},{"key":"10.1016\/j.toxicon.2011.04.019_bib14","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":"Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay","volume":"23","author":"Brin","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2011.04.019_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/sder.2001.24421","article-title":"Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology","volume":"20","author":"Callaway","year":"2001","journal-title":"Semin. Cutan. Med. Surg."},{"key":"10.1016\/j.toxicon.2011.04.019_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2146\/ajhp050137","article-title":"Unlabeled uses of botulinum toxins: a review, part 1","volume":"63","author":"Cheng","year":"2006","journal-title":"Am. J. Health Syst. Pharm"},{"key":"10.1016\/j.toxicon.2011.04.019_bib17","first-page":"CD003633","article-title":"Botulinum toxin type A therapy for cervical dystonia","volume":"25","author":"Costa","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.toxicon.2011.04.019_bib18","first-page":"CD004315","article-title":"Botulinum toxin type B for cervical dystonia","volume":"1","author":"Costa","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.toxicon.2011.04.019_bib19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2005.06.011","article-title":"Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases","volume":"53","author":"Cot\u00e9","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.toxicon.2011.04.019_bib20","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(99)01241-6","article-title":"Influenza","volume":"354","author":"Cox","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.toxicon.2011.04.019_bib21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/WNF.0b013e3181f5329e","article-title":"Systemic weakness after therapeutic injections of botulinum toxin A: a case series and review of the literature","volume":"33","author":"Crowner","year":"2010","journal-title":"Clin. Neuropharmacol"},{"key":"10.1016\/j.toxicon.2011.04.019_bib22","first-page":"15","article-title":"Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin","volume":"vol. 25","author":"DasGupta","year":"1994"},{"key":"10.1016\/j.toxicon.2011.04.019_bib23","article-title":"Association of HLA class II alleles and haplotypes with cervical dystonia: HLA DR13\u2013DQ6 (DQB1\u22170604) homozygotes are at greatly increased risk of cervical dystonia in Caucasian Americans","volume":"15","author":"Deitiker","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1016\/j.toxicon.2011.04.019_bib24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00702-010-0372-0","article-title":"Comparing botox and xeomin for axillar hyperhidrosis","volume":"117","author":"Dressler","year":"2010","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.toxicon.2011.04.019_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1468-1331.2010.03058.x","article-title":"Botulinum toxin for treatment of dystonia","volume":"17","author":"Dressler","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2011.04.019_bib70","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.toxicon.2010.12.019","article-title":"Studies on the dissociation of botulinum toxin type A complexes","volume":"57","author":"Eisele","year":"2011","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2011.04.019_bib26","series-title":"Myobloc, Botulinum Toxin Type B Injectable Solution. Prescribing Information","year":"2000"},{"key":"10.1016\/j.toxicon.2011.04.019_bib27","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/mds.20531","article-title":"Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia","volume":"20","author":"Factor","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2011.04.019_bib28","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2165\/00003495-200262040-00011","article-title":"Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia","volume":"62","author":"Figgitt","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.toxicon.2011.04.019_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-1331.2009.02879.x","article-title":"Xeomin: an innovative new botulinum toxin type A","volume":"16","author":"Frevert","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2011.04.019_bib30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","article-title":"Content of botulinum neurotoxin in botox(r)\/vistabel(r), dysport(r)\/azzalure(r), and xeomin(r)\/bocouture(r)","volume":"10","author":"Frevert","year":"2010","journal-title":"Drugs R. D."},{"key":"10.1016\/j.toxicon.2011.04.019_bib31","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/jnnp.55.9.844","article-title":"Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system","volume":"55","author":"Girlanda","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2011.04.019_bib32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/mds.870080411","article-title":"Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A","volume":"8","author":"Greene","year":"1993","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2011.04.019_bib33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","article-title":"Development of resistance to botulinum toxin type A in patients with torticollis","volume":"9","author":"Greene","year":"1994","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2011.04.019_bib34","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1526-4637.2006.00147.x","article-title":"Treatment of refractory, chronic low back pain with botulinum neurotoxin A: an open-label, pilot study","volume":"7","author":"Jabbari","year":"2006","journal-title":"Pain Med."},{"key":"10.1016\/j.toxicon.2011.04.019_bib35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1212\/WNL.40.2.277","article-title":"Botulinum toxin injections for cervical dystonia","volume":"40","author":"Jankovic","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2011.04.019_bib36","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","article-title":"Response and immunoresistance to botulinum toxin injections","volume":"45","author":"Jankovic","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2011.04.019_bib37","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia","volume":"60","author":"Jankovic","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2011.04.019_bib38","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1212\/01.wnl.0000249308.66959.43","article-title":"Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia","volume":"67","author":"Jankovic","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2011.04.019_bib39","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.toxicon.2009.01.007","article-title":"Unique properties of botulinum toxins","volume":"54","author":"Jankovic","year":"2009","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2011.04.019_bib40","first-page":"144","article-title":"Botulinum toxin","volume":"vol. 1","author":"Jankovic","year":"2010"},{"key":"10.1016\/j.toxicon.2011.04.019_bib41","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0072-9752(07)01511-4","article-title":"Botulism","volume":"91","author":"Johnson","year":"2008","journal-title":"Handb Clin. Neurol."},{"key":"10.1016\/j.toxicon.2011.04.019_bib42","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1212\/01.WNL.0000142040.57474.A6","article-title":"Botulinum toxin effect on salivary flow rate in children with cerebral palsy","volume":"63","author":"Jongerius","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2011.04.019_bib43","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1099\/mic.0.28421-0","article-title":"Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin","volume":"151","author":"Lee","year":"2005","journal-title":"Microbiology"},{"key":"10.1016\/j.toxicon.2011.04.019_bib44","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.49.3.701","article-title":"Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia","volume":"49","author":"Lew","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2011.04.019_bib45","first-page":"29","article-title":"The safety and efficacy of Botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials","volume":"55","author":"Lew","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2011.04.019_bib46","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.disamonth.2009.01.001","article-title":"Complications of botulinum neurotoxin","volume":"55","author":"Lu","year":"2009","journal-title":"Dis. Mon"},{"key":"10.1016\/j.toxicon.2011.04.019_bib47","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/00042737-200208000-00007","article-title":"Side effects of botulinum toxin injection for benign anal disorders","volume":"14","author":"Madali\u0144ski","year":"2002","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.toxicon.2011.04.019_bib48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s10072-005-0378-9","article-title":"A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (botox) for the treatment of spastic foot","volume":"26","author":"Mancini","year":"2005","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.toxicon.2011.04.019_bib49","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/mds.20376","article-title":"Long-term botulinum toxin efficacy, safety, and immunogenicity","volume":"20","author":"Mejia","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2011.04.019_bib50","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.biochem.051908.125345","article-title":"Botulinum neurotoxin: a marvel of protein design","volume":"79","author":"Montal","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.toxicon.2011.04.019_bib51","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1212\/01.wnl.0000316801.74683.c0","article-title":"Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy","volume":"71","author":"Moore","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2011.04.019_bib52","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1185\/03007990802329959","article-title":"Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis","volume":"24","author":"Moses","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.toxicon.2011.04.019_bib53","first-page":"455","article-title":"Botulinum toxins: pharmacology and its current therapeutic evidence for use","volume":"51","author":"Muthane","year":"2003","journal-title":"Neurol. India"},{"key":"10.1016\/j.toxicon.2011.04.019_bib54","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1185\/030079904125003962","article-title":"Safety of botulinumtoxin type A: a systematic review and meta-analysis","volume":"20","author":"Naumann","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.toxicon.2011.04.019_bib55","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1468-1331.2006.01652.x","article-title":"Safety and efficacy of botulinum toxin type A following long-term use","volume":"4","author":"Naumann","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2011.04.019_bib56","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.ajp.0000174267.06993.3f","article-title":"Treatment of chronic low back pain with successive injections of botulinum toxin a over 6 months: a prospective trial of 60 patients","volume":"22","author":"Ney","year":"2006","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.toxicon.2011.04.019_bib57","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.64.1.6","article-title":"A double blind, randomized, parallel group study to investigate the dose equivalence of dysport and botox in the treatment of cervical dystonia","volume":"64","author":"Odergren","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2011.04.019_bib58","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1348-0421.1995.tb02184.x","article-title":"Structure and function of Clostridium botulinum toxins","volume":"39","author":"Oguma","year":"1995","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.toxicon.2011.04.019_bib59","first-page":"277","article-title":"Effectiveness of botulinum toxin A in the treatment of spasticity of the lower extremities in adults \u2013 preliminary report","volume":"9","author":"Opara","year":"2007","journal-title":"Ortop. Traumatol. Rehabil."},{"key":"10.1016\/j.toxicon.2011.04.019_bib60","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","article-title":"Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm","volume":"113","author":"Roggenk\u00e4mper","year":"2006","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.toxicon.2011.04.019_bib61","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1542\/peds.2006-2425","article-title":"Upper-limb botulinum toxin A injection and occupational therapy in children with hemiplegic cerebral palsy identified from a population register: a single-blind, randomized, controlled trial","volume":"119","author":"Russo","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.toxicon.2011.04.019_bib62","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0163-7258(82)90061-4","article-title":"Clostridium botulinum toxins","volume":"19","author":"Sakaguchi","year":"1983","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.toxicon.2011.04.019_bib63","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2165\/00128071-200405020-00004","article-title":"Levamisole in dermatology: a review","volume":"5","author":"Scheinfeld","year":"2004","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.toxicon.2011.04.019_bib64","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1152\/physrev.2000.80.2.717","article-title":"Neurotoxins affecting neuroexocytosis","volume":"80","author":"Schiavo","year":"2000","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.toxicon.2011.04.019_bib65","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1749-6632.1994.tb26614.x","article-title":"Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus","volume":"710","author":"Schiavo","year":"1994","journal-title":"Ann. N. Y Acad. Sci."},{"key":"10.1016\/j.toxicon.2011.04.019_bib66","first-page":"22","article-title":"The biochemistry of botulinum toxin type B","volume":"55","author":"Setler","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2011.04.019_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14260","article-title":"BoTULS: a multicentre randomized controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A","volume":"14","author":"Shaw","year":"2010","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.toxicon.2011.04.019_bib68","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","article-title":"Long-term efficacy and safety of botulinum toxin type A (dysport) in cervical dystonia","author":"Truong","year":"2010","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.toxicon.2011.04.019_bib69","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0304-3959(01)00358-X","article-title":"Botulinum toxin A for the treatment of chronic neck pain","volume":"94","author":"Wheeler","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.toxicon.2011.04.019_bib71","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.WNF.0000240951.18821.50","article-title":"Neurophysiological double blind trial of botulinum neurotoxin type A free of complexing proteins","volume":"30","author":"Wohlfarth","year":"2007","journal-title":"Clin. Neuropharmacol."}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010111001541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010111001541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T22:15:42Z","timestamp":1560204942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010111001541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0041010111001541"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2011.04.019","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}